skepinone-L

Skepinone-L is a highly potent, selective, ATP-competitive small molecule inhibitor of p38 mitogen-activated protein kinase (MAPK), specifically targeting the p38α (MAPK14) and p38β (MAPK11) isoforms. Developed by researchers at the Eberhard Karls University of Tübingen, Skepinone-L was designed to achieve high selectivity by inducing a glycine-flip in the hinge region and targeting hydrophobic region I of the kinase. It is currently being evaluated in a Phase 1 clinical trial in combination with sorafenib for the treatment of advanced non-viral hepatocellular carcinoma (HCC), where p38 MAPK inhibition has been shown to overcome resistance to sorafenib.

Other names

Skepinone-Lp38 MAP Kinase Inhibitor XIXp-38 MAP Kinase Inhibitor XIXp 38 MAP Kinase Inhibitor XIX